Abstract
Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that mainly erodes joints and surrounding tissues, and if it is not treated in time, it can cause joint deformities and loss of function. S-propargyl-cysteine (SPRC) is an excellent endogenous hydrogen sulfide donor which can relieve the symptoms of RA through the promotion of H2 S release via the CSE/H2 S pathway in vivo. However, the instant release of H2 S in vivo could potentially limit its further clinical use. To solve this problem, in this study, a SPRC-loaded poly(lactic acid) (PLA) microsphere (SPRC@PLA) was prepared, which could release SPRC in vitro in a sustained manner, and further promote sustained in vivo H2 S release. Furthermore, its therapeutical effect on RA in rats was also studied. A spherical-like SPRC@PLA was successfully prepared with a diameter of approximately 31.61 µm, yielding rate of 50.66%, loading efficiency of 6.10% and encapsulation efficiency of 52.71%. The SPRC@PLA showed significant prolonged in vitro SPRC release, to 4 days, and additionally, an in vivo H2 S release around 3 days could also be observed. In addition, a better therapeutical effect and prolonged administration interval toward RA rats was also observed in the SPRC@PLA group.
Author supplied keywords
Cite
CITATION STYLE
Yu, Y., Wang, Z., Ding, Q., Yu, X., Yang, Q., Wang, R., … Zhu, Y. (2021). The preparation of a novel poly(Lactic acid)-based sustained h2 s releasing microsphere for rheumatoid arthritis alleviation. Pharmaceutics, 13(5). https://doi.org/10.3390/pharmaceutics13050742
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.